他拉唑帕利联合恩扎卢胺对比奥拉帕利联合阿比特龙醋酸酯及尼拉帕利联合阿比特龙醋酸酯治疗转移性去势抵抗性前列腺癌:一项匹配调整间接比较
本研究通过匹配调整间接比较(MAIC),利用TALAPRO-2患者个体数据及PROpel与MAGNITUDE已发表数据,比较他拉唑帕利联合恩扎卢胺(TALA+ENZA)与奥拉帕利联合阿比特龙醋酸酯(OLAP+AAP)、尼拉帕利联合阿比特龙醋酸酯(NIRA+AAP)一线治疗转移性去势抵抗性前列腺癌(mCRPC)的相对疗效。在全人群,TALA+ENZA较OLAP+AAP的影像学无进展生存期(rPFS)和PSA缓解具统计学优势;在同源重组修复突变(HRRm)患者中,TALA+ENZA较NIRA+AAP的rPFS具统计学优势。结果提示TALA+ENZA可能改善临床结局,但须考虑分析复杂性相关的固有局限。
要点
- 全人群中TALA+ENZA较OLAP+AAP的rPFS具统计学优势(HR 0.727;95%CI 0.565,0.935)。
- 全人群中TALA+ENZA较OLAP+AAP的PSA缓解具统计学优势(OR 1.663;95%CI 1.101,2.510)。
- HRRm患者中TALA+ENZA较NIRA+AAP的rPFS具统计学优势(HR 0.460;95%CI 0.280,0.754)。
核心结论
- 结果提示TALA+ENZA相比OLAP+AAP和NIRA+AAP在一线mCRPC中可能改善临床结局,但须考虑分析复杂性相关的固有局限。
研究设计与样本
- 匹配调整间接治疗比较(MAIC),使用TALAPRO-2的患者个体数据及PROpel和MAGNITUDE的已发表数据,将TALAPRO-2数据重新加权以满足PROpel和MAGNITUDE的入选标准。
主要发现
- 全人群中TALA+ENZA较OLAP+AAP的rPFS具统计学优势(HR 0.727;95%CI 0.565,0.935),PSA缓解具统计学优势(OR 1.663;95%CI 1.101,2.510)。
- 全人群中TALA+ENZA较OLAP+AAP的OS在数值上有利(HR 0.847;95%CI 0.667,1.076),ORR在数值上有利(OR 1.109;95%CI 0.646,1.903)。
- HRRm患者中TALA+ENZA较NIRA+AAP的rPFS具统计学优势(HR 0.460;95%CI 0.280,0.754)。
- HRRm患者中TALA+ENZA较NIRA+AAP的OS在数值上有利(HR 0.601;95%CI 0.347,1.041),ORR在数值上有利(OR 1.524;95%CI 0.579,4.016)。
关键数值与推荐
- TALA+ENZA方案:他拉唑帕利0.5 mg/日联合恩扎卢胺160 mg/日。
- OLAP+AAP方案:奥拉帕利300 mg每日两次联合阿比特龙醋酸酯1000 mg/日。
- NIRA+AAP方案:尼拉帕利200 mg/日联合阿比特龙醋酸酯1000 mg/日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出必须考虑与这些分析复杂性相关的固有局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Without head-to-head trials between talazoparib+enzalutamide (TALA + ENZA), olaparib+abiraterone acetate (OLAP + AAP), and niraparib plus AAP (NIRA + AAP) the ability to evaluate their relative efficacy as first-line (1 L) treatment in metastatic castration-resistant prostate cancer (mCRPC) is limited. The objective of this study was to assess the relative efficacy between TALA + ENZA (TALAPRO-2) versus OLAP + AAP (PROpel) and NIRA + AAP (MAGNITUDE) in 1 L mCRPC via a matching-adjusted indirect treatment comparison (MAIC). METHODS: Patient-level data from TALAPRO-2 and published data from PROpel and MAGNITUDE were used. TALAPRO-2 data were reweighted to satisfy the eligibility criteria for PROpel and MAGNITUDE. Talazoparib (0.5 mg/day) plus enzalutamide (160 mg/day) was compared to olaparib (300 mg twice daily) plus abiraterone acetate (1000 mg/day) and niraparib (200 mg/day) plus abiraterone acetate (1000 mg/day). Hazard ratios (HRs) were calculated for radiographic progression-free survival (rPFS) and overall survival (OS), and odds ratios (ORs) for prostate-specific antigen (PSA) response and objective response rate (ORR). Additional efficacy outcomes were assessed. RESULTS: In all-comers, TALA + ENZA was statistically superior to OLAP + AAP for rPFS (HR: 0.727; 95% confidence interval [CI]: 0.565, 0.935) and PSA response (OR: 1.663; 1.101, 2.510), and numerically favored for OS (HR: 0.847; 0.667, 1.076) and ORR (OR: 1.109; 0.646, 1.903). In patients with homologous recombination repair mutations (HRRm), relative to NIRA + AAP, TALA + ENZA was statistically superior for rPFS (HR: 0.460; 0.280, 0.754), and numerically favored for OS (HR: 0.601; 0.347, 1.041) and ORR (OR: 1.524; 0.579, 4.016). CONCLUSIONS: Results suggest that TALA + ENZA may provide improvements in clinical outcomes relative to OLAP + AAP and NIRA + AAP in 1 L mCRPC; however, inherent limitations associated with the complexity of the analyses must be considered.
引用
- Castro E, Wang D, Walsh S, et al. Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. Prostate Cancer Prostatic Dis. 2024. PMID: 39645562. doi:10.1038/s41391-024-00924-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。